GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rani Therapeutics Holdings Inc (NAS:RANI) » Definitions » Operating Margin %

Rani Therapeutics Holdings (Rani Therapeutics Holdings) Operating Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rani Therapeutics Holdings Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Rani Therapeutics Holdings's Operating Income for the three months ended in Mar. 2024 was $-14.03 Mil. Rani Therapeutics Holdings's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Rani Therapeutics Holdings's Operating Margin % for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Rani Therapeutics Holdings's Operating Margin % or its related term are showing as below:


RANI's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -166.59
* Ranked among companies with meaningful Operating Margin % only.

Rani Therapeutics Holdings's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Rani Therapeutics Holdings's Operating Income for the three months ended in Mar. 2024 was $-14.03 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-63.62 Mil.


Rani Therapeutics Holdings Operating Margin % Historical Data

The historical data trend for Rani Therapeutics Holdings's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rani Therapeutics Holdings Operating Margin % Chart

Rani Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
-2,764.56 -3,580.95 -1,899.12 - -

Rani Therapeutics Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rani Therapeutics Holdings's Operating Margin %

For the Biotechnology subindustry, Rani Therapeutics Holdings's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rani Therapeutics Holdings's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Rani Therapeutics Holdings's Operating Margin % falls into.



Rani Therapeutics Holdings Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Rani Therapeutics Holdings's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-66.099 / 0
= %

Rani Therapeutics Holdings's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-14.034 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rani Therapeutics Holdings  (NAS:RANI) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Rani Therapeutics Holdings Operating Margin % Related Terms

Thank you for viewing the detailed overview of Rani Therapeutics Holdings's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rani Therapeutics Holdings (Rani Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. The company has developed the RaniPill capsule, a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
Executives
Talat Imran director, officer: CEO C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Cone Investments Limited Partnership 10 percent owner AVENIDA PRESIDENTE RIESCO 5711 OFICINA 1, LAS CONDES, SANTIAGO F3 7550000
Quiroga Cortes Isidoro Alfonso 10 percent owner 9020 N CAPITAL OF TEXAS HWY, SUITE I-260, AUSTIN TX 78759
Jean Luc Butel director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Maulik Nanavaty director BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Kate Mckinley officer: CHIEF BUSINESS OFFICER C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Svai S Sanford officer: CFO C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE., SAN JOSE CA 95131
Eric Groen officer: General Counsel C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Mir Hashim officer: Chief Scientific Officer C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Lake One Llc 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Aequanimitas Limited Partnership 10 percent owner LEONEL AGUIRRE 1830, UNIT 101, MONTEVIDEO X3 11500
Mir A Imran director
Andrew Farquharson director C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
Laureen Debuono director
Lisa Ann Rometty director C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131